Feeds:
Posts
Comments

Search Results for 'Pharmacotherapy of Cardiovascular Disease'

Omecamtiv mecarbil – A study examined efficacy and tolerability in Heart Failure patients with SBP ≤100 mmHg enrolled in GALACTIC-HF Reporter: Aviva Lev-Ari, PhD, RN Effects of Omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial  Marco Metra, MD, Matteo Pagnesi, MD, Brian L. Claggett, PhD, Rafael Díaz, MD, G. Michael Felker, […]

Read Full Post »

The Framingham Study: Across 6 Decades, Cardiovascular Disease Among Middle-Aged Adults – mean life expectancy increased and the RLR of ASCVD decreased. Effective primary prevention efforts and better screening increased. Reporter: Aviva Lev-Ari, PhD, RN Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study Ramachandran […]

Read Full Post »

WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com Curators: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD, Aviva Lev-Ari, PhD, RN     Work by Summer Interns in 2020 Updated on 2/22/2022 by Aviva Lev-Ari, PhD, RN NEW ARTICLE ARE IN […]

Read Full Post »

Zachary Day, Research Assistant 2, Exploration in Marketing Communications https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/zachary-day-research-assistant-2-exploration-in-marketing-communications/ Assignment #4 Article Information Article NameLive Link Views All Time Categories of Research Interaction of enzymes and hormones 5,179 Cell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Metabolomics, Population Health Management, Genetics & Pharmaceutical, Population Health Management, Nutrition and […]

Read Full Post »

2022 Update from LPBI Group Author & Curator: Aviva Lev-Ari, PhD, RN Picture on 2/6/2022 BIO https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/aviva-lev-ari-phd-rn-founder-lpbi-group-1-0-2-0/   UPDATED on 4/25/2022 We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022 https://pharmaceuticalintelligence.com/2022/04/25/we-celebrate-ten-years-of-excellence-lpbi-group-4-2012-4-2022/   UPDATED on 3/10/2022   LPBI Group https://pharmaceuticalintelligence.com/ offers the opportunity to play a pivotal role in Founder’s quest for Transfer of […]

Read Full Post »

Transthyretin amyloid cardiomyopathy (ATTR-CM): U.S. FDA APPROVES VYNDAQEL® AND VYNDAMAX™ for this Rare and Fatal Disease Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 6/30/2021 CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis June 26, 2021 DOI: 10.1056/NEJMoa2107454 Abstract Background Transthyretin amyloidosis, also called ATTR amyloidosis, is a life-threatening disease characterized by progressive accumulation of misfolded […]

Read Full Post »

Risks from Dual Antiplatelet Therapy (DAPT) may be reduced by Genotyping Guidance of Cardiac Patients Reporter: Aviva Lev-Ari, PhD, RN   Genotyping Cardiac Patients May Reduce Risks From DAPT -STEMI patient study reaches noninferiority mark for adverse cardiac events by Vicki Brower, CME Writer, MedPage Today September 7, 2019 In the investigational arm, all 1,242 patients were tested […]

Read Full Post »

Cardiovascular (CV) Disease and Diabetes: New ACC Guidelines for use of two major new classes of diabetes drugs — sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs) for reduction of adverse outcomes Reporter: Aviva Lev-Ari, PhD, RN   “The main aim for this report is to educate cardiologists, who might not otherwise think […]

Read Full Post »

Injectable inclisiran (siRNA) as 3rd anti-PCSK9 behind mAbs Repatha and Praluent Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 4/27/2021 Combining AstraZeneca’s ‘good’ cholesterol booster with PCSK9 inhibition shows promise in heart disease by Angus Liu | Apr 21, 2021 3:00pm The drug, dubbed MEDI5884, is designed to neutralize a circulating enzyme called endothelial lipase. The protein regulates […]

Read Full Post »

@Cleveland Clinic – Serial measurements of high-sensitivity C-reactive protein (hsCRP) post acute coronary syndrome (ACS) may help identify patients at higher risk for morbidity and mortality   Reporter: Aviva Lev-Ari, PhD, RN   Original Investigation March 6, 2019 Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary […]

Read Full Post »

Next »

%d bloggers like this: